Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB15 hours ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB15 hours ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB12 hours ago · SNY. REGN. GLDAF. The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market ...
INVESTORS & MEDIA - newsroom.regeneron.com
WEB15 hours ago · TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and ...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
WEB8 hours ago · Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB15 hours ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB15 hours ago · Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to ...
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · About Sanofi and Regeneron’s COPD Clinical Research Program. Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Regeneron and Sanofi Provide Update on Dupixent® …
WEBOct 20, 2023 · TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) in chronic spontaneous urticaria (CSU). ). CSU is an inflammatory skin condition ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB1 day ago · For Regeneron, which splits U.S. Dupixent revenue with Sanofi, the COPD approval is a needed boost. The company lost nearly $14 billion of its market value earlier this week after a setback in a ...